title: Safety and efficacy of a novel drug elores (ceftriaxone+sulbactam+disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: a post-marketing surveillance study.
abstract: OBJECTIVE
  In India, Elores (CSE-1034: ceftriaxone+sulbactam+disodium edetate) was approved as a broad spectrum antibiotic in year 2011 and is used for management of Extended Spectrum Beta Lactamases/Metallo Beta lactamases infections in tertiary care centers. The objective of this study was to investigate the efficacy of this drug in patients with Extended Spectrum Beta Lactamases/Metallo Beta lactamases infections and identify the incidence of adverse events in real clinical settings.
  
  
  METHODS
  This Post Marketing Surveillance study was conducted at 17 centers across India and included 2500 patients of all age groups suffering from various bacterial infections and treated with Elores (CSE1034). Information regarding demographic, clinical and microbiological parameters, dosage and treatment duration, efficacy and adverse events (AEs) associated with the treatment were recorded.
  
  
  RESULTS
  A total of 2500 patients were included in the study and efficacy was evaluated in 2487 patients. In total, 409 AEs were reported in 211 (8.4%) patients. The major AEs reported were vomiting (3.0%), pain at injection site (2.5%), nausea (2.3%), redness at site (1.96%), thrombophlebitis (1.4%). Of total reported AEs, 40 (5.3%) AEs were reported in pediatric, 310 (20.6%) in adult, and 59 (23.6%) in geriatric group. No AE belonging to grade IV or V was reported in any patient. In terms of efficacy, 1977 (79.4%) patients were cured, 501 (20.1%) patients showed clinical improvement and 5 (0.2%) patients were complete failure. The treatment duration varied from 5 to 7 days in different patients depending on the infection type.
  
  
  CONCLUSIONS
  In this post-marketing surveillance study, CSE-1034 was found to be an effective and safe option against Pip tazo and meropenem in management of patients with multi-drug resistant (MDR) bacterial infections under routine ward settings.
authors.affiliation: Venus Remedies, Department of Clinical Research, Panchkula, India.
authors.forename: Manu
authors.initials: M
authors.lastname: Chaudhary
authors.affiliation: Venus Remedies, Department of Clinical Research, Panchkula, India. Electronic address: medcom@vmrcindia.com.
authors.forename: Mohd Amin
authors.initials: MA
authors.lastname: Mir
authors.affiliation: Venus Remedies, Department of Clinical Research, Panchkula, India.
authors.forename: Shiekh Gazalla
authors.initials: SG
authors.lastname: Ayub
authors.affiliation: Venus Remedies, Department of Clinical Research, Panchkula, India.
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry; D002443:Ceftriaxone / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D052978:Disk Diffusion Antimicrobial Tests; D004338:Drug Combinations; D024881:Drug Resistance, Bacterial; D004492:Edetic Acid / Q000008:administration & dosage / Q000009:adverse effects; D006090:Gram-Negative Bacteria / Q000145:classification / Q000187:drug effects*; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy / Q000382:microbiology*; D006094:Gram-Positive Bacteria / Q000145:classification / Q000187:drug effects*; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy / Q000382:microbiology*; D006801:Humans; D007194:India; D013407:Sulbactam / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D002443:Ceftriaxone; D004492:Edetic Acid; D013407:Sulbactam
keywords: Bacterial infections; CSE-1034; IPD; Multi-drug resistance